Diisopropylethylamine → Trifluoroacetic acid

HRID 1162741노트

반응식

HRID 1162741 반응식
[F:1][C:2]([F:29])([F:28])[C:3]1[C:11]2[CH2:10][CH2:9][CH2:8][CH2:7][C:6]=2[N:5]([CH2:12][C:13]([NH:15][C:16]2[S:20][C:19]3[CH2:21][CH2:22][CH2:23][CH2:24][C:18]=3[C:17]=2[C:25]([OH:27])=O)=[O:14])[N:4]=1.F[P-](F)(F)(F)(F)F.N1(OC(N(C)C)=[N+](C)C)[C:41]2[N:42]=[CH:43]C=C[C:40]=2[N:39]=N1.C([O:58][C:59](=[O:65])N(CCN)C)(C)(C)C.C(N(CC)C(C)C)(C)C>C(Cl)Cl.CN(C=O)C>[CH3:43][NH:42][CH2:41][CH2:40][NH:39][C:25]([C:17]1[C:18]2[CH2:24][CH2:23][CH2:22][CH2:21][C:19]=2[S:20][C:16]=1[NH:15][C:13](=[O:14])[CH2:12][N:5]1[C:6]2[CH2:7][CH2:8][CH2:9][CH2:10][C:11]=2[C:3]([C:2]([F:28])([F:1])[F:29])=[N:4]1)=[O:27].[C:59]([OH:58])([C:2]([F:29])([F:28])[F:1])=[O:65]

참가 물질

8

반응물 4

HCID 81531DiisopropylethylamineHCID 2756424N-Boc-N-methylethylenediamineHCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 595204832-[2-(3-Trifluoromethyl-4,5,6,7-tetrahydroindazol-1-yl)-acetylamino]-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid

생성물 2

HCID 6422Trifluoroacetic acid수율 445.9%HCID 529492432-[2-(3-Trifluoromethyl-4,5,6,7-tetrahydroindazol-1-yl)-acetylamino]-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid (2-methylamino-ethyl)-amide

시약·촉매·용매 2

HCID 6228Dimethylformamide용매HCID 6344Dichloromethane용매

실험 절차

2-[2-(3-Trifluoromethyl-4,5,6,7-tetrahydroindazol-1-yl)-acetylamino]-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid (25 mg, 0.059 mmol) was dissolved in a solution of DCM (1 mL) and DMF (0.2 mL). O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (27 mg, 0.070 mmol) was added, followed by N-(2-aminoethyl)-N-methyl carbamic acid tert-butyl ester (12 mg, 0.070 mmol) and N,N-diisopropylethylamine (12.2 μL, 0.070 mmol). The resultant mixture was stirred at RT overnight. The solvent was removed under reduced pressure, and the residue obtained purified by preparative reverse phase HPLC. The resulting residue was dissolved in a solution of DCM (0.5 mL) and TFA (0.5 mL) and stirred at RT for 30 min, before concentration in vacuo. The residue obtained was purified by preparative reverse phase HPLC to yield the title compound as a TFA salt (15 mg, 0.025, 42%).

후처리

  1. customThe solvent was removed under reduced pressure
  2. customthe residue obtained
  3. custompurified by preparative reverse phase HPLC
  4. dissolutionThe resulting residue was dissolved in a solution of DCM (0.5 mL) and TFA (0.5 mL)
  5. customThe residue obtained
  6. customwas purified by preparative reverse phase HPLC

출처 및 근거

ORD 기록
ord-b2e9f6290feb49bf902633aa6f374051
출처 데이터셋
uspto-grants-2010_10
특허 번호
US07820707B2

반응 노트

불러오는 중…